Our results indicate that mRNA-based vaccination is more effective, especially regarding a CD8+ T cell response, when administered to individuals with actual virus experience, a phenomenon known as hybrid immunity in general and here confirmed for patients with cancer in particular. The gene discussed is CD8A; the disease is cancer.